Clinical trial
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic…
NCT00325078 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00325078 |
|---|---|
| Title | Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease |
| Official title | Tumor Necrosis Factor Alpha Inhibitor (Lnfliximab, Adalimumab) Treatment for Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD) |
| Intervention type | Drug |
| Interventions | Infliximab |
| Enrollment | 40 |
| Start date | May 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | May 12, 2006 |
| Last update posted | Dec 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: